NASH

Our portfolio covers the full spectrum of chronic liver disease progression - from non-alcoholic fatty liver disease (NAFLD) and steatosis into non-alcoholic steatohepatitis (NASH): inflammation of the liver and fibrosis. 

 
nash-4.jpg
T-101B-v2.jpg

TERN-101: Farnesoid X Receptor (FXR) Agonism

FXR is a nuclear receptor that is highly expressed in the liver and small intestine. Bile acids (BA) are natural ligands of FXR, and their binding with and activation of FXR is critical to the regulation of cellular pathways that modulate BA synthesis, lipid metabolism, inflammation and fibrosis. It is believed by many in the scientific community that FXR agonism and activation has potential as a new treatment modality for nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). TERN-101 has demonstrated potential in a preclinical setting as an effective non-bile acid FXR agonist for the treatment of NASH. POSTER

T-201-v2.jpg

TERN-201: Semicarbazide-Sensitive Amine Oxidase (SSAO) Inhibition

SSAO, also known as VAP-1 (Vascular Adhesion Protein-1), is a dual-function amine oxidase which increases oxidative stress through the generation of H2O2 and promotes recruitment of white blood cells in the liver, which results in increased oxidative stress, inflammation and hepatic fibrosis. The level of surface SSAO is upregulated in the vasculature of inflamed tissues, and soluble SSAO levels are elevated in patients with NASH. Inhibition of SSAO is believed to have therapeutic benefit for the treatment of NAFLD, NASH and other chronic fibrotic liver diseases by reducing oxidative stress and recruitment of white blood cells to the liver. TERN-201 has demonstrated potential in a preclinical setting as an SSAO inhibitor which provides an additional treatment mechanism for NASH. POSTER


THR-β

Excessive hepatic lipid synthesis leads to hepatic fat accumulation and steatohepatitis. Steatosis is a contributing early driver of NAFLD, and eventually NASH. Thyroid hormones regulate plasma cholesterol, triglycerides, and lipid metabolism in multiple tissues including the liver. Selective thyroid hormone receptor activation in the liver is therefore a promising target to adjust lipid metabolism dysregulation associated with NASH by reducing cholesterol and triglycerides, while avoiding off-target effects (e.g. heart tissues). The reduction of hepatic steatosis has the potential for significant impact on NASH as it removes the key driver of inflammation. Terns is pursuing a novel therapeutic approach to selectively activate the β thyroid hormone receptor in the liver.


ASK1

Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinases (MAPK) family, is activated by multiple stimuli, including oxidative and endoplasmic reticulum (ER) stress, resulting in downstream p38 and c-Jun N-terminal kinases (JNK) pathway activation. An activated ASK1 pathway is found in the livers of NASH patients leading to the induction of stress response pathways that worsen hepatic inflammation, apoptosis, and fibrosis. Terns is exploring pharmacologic inhibition of ASK1 as a novel therapy for NAFLD and NASH patients.


About NASH

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. It is estimated that 15 percent of the Chinese adult population has NAFLD. Of those patients, an estimated 20 percent will develop NASH. There is currently no approved medication for the treatment of NASH.